Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth

Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Leave a comment

Your email address will not be published. Required fields are marked *